{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:24:57Z","timestamp":1772252697633,"version":"3.50.1"},"reference-count":228,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01383"],"award-info":[{"award-number":["PI18\/01383"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI2018-094005-B-I00"],"award-info":[{"award-number":["RTI2018-094005-B-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie Stiftung","award":["DJCLS 14R\/2018"],"award-info":[{"award-number":["DJCLS 14R\/2018"]}]},{"DOI":"10.13039\/501100003030","name":"Agency for Administration of University and Research","doi-asserted-by":"publisher","award":["2017-SGR-305"],"award-info":[{"award-number":["2017-SGR-305"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"La Marat\u00f3 de TV3","award":["257\/C\/2019"],"award-info":[{"award-number":["257\/C\/2019"]}]},{"name":"Marie Sk\u0142odowska Curie Training network","award":["H2020-MSCA-ITN-2020-953407"],"award-info":[{"award-number":["H2020-MSCA-ITN-2020-953407"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.<\/jats:p>","DOI":"10.3390\/ijms23010253","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T01:18:15Z","timestamp":1640654295000},"page":"253","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Histone Modifications and Their Targeting in Lymphoid Malignancies"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-8496","authenticated-orcid":false,"given":"Miranda","family":"Fern\u00e1ndez-Serrano","sequence":"first","affiliation":[{"name":"Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"},{"name":"Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08014 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-0242","authenticated-orcid":false,"given":"Ren\u00e9","family":"Winkler","sequence":"additional","affiliation":[{"name":"Chromatin, Metabolism and Cell Fate Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4148-9570","authenticated-orcid":false,"given":"Juliana C.","family":"Santos","sequence":"additional","affiliation":[{"name":"Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-8805","authenticated-orcid":false,"given":"Marguerite-Marie","family":"Le Pann\u00e9rer","sequence":"additional","affiliation":[{"name":"Chromatin, Metabolism and Cell Fate Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3218-4567","authenticated-orcid":false,"given":"Marcus","family":"Buschbeck","sequence":"additional","affiliation":[{"name":"Chromatin, Metabolism and Cell Fate Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"},{"name":"Program of Personalized and Predictive Medicine of Cancer, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-2257","authenticated-orcid":false,"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[{"name":"Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"},{"name":"Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08014 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_4","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Diffuse Large B-Cell Lymphoma, NOS. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_6","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Follicular lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_9","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Burkitt Lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2018.07.013","article-title":"Burkitt lymphoma- a rare but challenging lymphoma","volume":"31","author":"Casulo","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_11","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Splenic Marginal Zone Lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_12","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Nodal Marginal Zone Lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_13","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal Zone Lymphoma: State-of-the-Art Treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_15","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Mantle Cell Lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC)."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rou\u00e9, G., and Sola, B. (2020). Management of drug resistance in mantle cell lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12061565"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ije\/dyr184","article-title":"The epigenotype. 1942","volume":"41","author":"Waddington","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg3207","article-title":"Transcription factors: From enhancer binding to developmental control","volume":"13","author":"Spitz","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1101\/gad.307702.117","article-title":"Chromatin and nucleosome dynamics in DNA damage and repair","volume":"31","author":"Hauer","year":"2017","journal-title":"Genes Dev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cell.2020.09.014","article-title":"The Self-Organizing Genome: Principles of Genome Architecture and Function","volume":"183","author":"Misteli","year":"2020","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.tibs.2020.01.002","article-title":"Mechanisms and Functions of Chromosome Compartmentalization","volume":"45","author":"Hildebrand","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrg2522","article-title":"Nucleosome positioning and gene regulation: Advances through genomics","volume":"10","author":"Jiang","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-020-02002-6","article-title":"Hi-D: Nanoscale mapping of nuclear dynamics in single living cells","volume":"21","author":"Shaban","year":"2020","journal-title":"Genome Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 \u00c5 resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.molcel.2018.09.027","article-title":"Structure of an H1-Bound 6-Nucleosome Array Reveals an Untwisted Two-Start Chromatin Fiber Conformation","volume":"72","author":"Menoni","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrm.2016.166","article-title":"Variants of core histones and their roles in cell fate decisions, development and cancer","volume":"18","author":"Buschbeck","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm3890","article-title":"Histone core modifications regulating nucleosome structure and dynamics","volume":"15","author":"Tessarz","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nsmb.2581","article-title":"Scratching the (lateral) surface of chromatin regulation by histone modifications","volume":"20","author":"Tropberger","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-020-00736-4","article-title":"Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation","volume":"52","author":"Morgan","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","article-title":"Histone Acetyltransferases","volume":"70","author":"Roth","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Parra","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/febs.13053","article-title":"Sirtuin-dependent epigenetic regulation in the maintenance of genome integrity","volume":"282","author":"Vaquero","year":"2015","journal-title":"FEBS J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13148-016-0223-4","article-title":"Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy","volume":"8","author":"Morera","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1878-0261.12744","article-title":"The DNA methylation landscape of hematological malignancies: An update","volume":"14","author":"Blecua","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"35534","DOI":"10.1074\/jbc.M113.510669","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) Silencing","volume":"288","author":"Chung","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Poole, C.J., and van Riggelen, J. (2017). MYC\u2014master regulator of the cancer epigenome and transcriptome. Genes, 8.","DOI":"10.3390\/genes8050142"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cell.2004.09.014","article-title":"MTA3 and the Mi-2\/NuRD complex regulate cell fate during B lymphocyte differentiation","volume":"119","author":"Fujita","year":"2004","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22045","DOI":"10.1074\/jbc.M201736200","article-title":"Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor","volume":"277","author":"Lemercier","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6880","DOI":"10.1128\/MCB.00630-06","article-title":"Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets","volume":"26","author":"Gearhart","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: Seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: Can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of TSA and SAHA","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Guan, X., Lin, P., Knoll, E., and Chakrabarti, R. (2014). Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: Computational and experimental studies. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107729"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E2772","DOI":"10.1073\/pnas.1303628110","article-title":"Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism","volume":"110","author":"Gertz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/bies.950170510","article-title":"Rn Trichostatin A and trapoxin: Novel","volume":"17","author":"Yoshida","year":"1995","journal-title":"BioEssays"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2147\/DDDT.S78276","article-title":"HDACiDB: A database for histone deacetylase inhibitors","volume":"9","author":"Murugan","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","article-title":"Next-generation of selective histone deacetylase inhibitors","volume":"9","author":"Yang","year":"2019","journal-title":"RSC Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acsmedchemlett.0c00462","article-title":"Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejmech.2018.04.046","article-title":"Design and biological evaluation of tetrahydro-\u03b2-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors","volume":"152","author":"Leonhardt","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunglubulin enhancers iduces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"key":"ref_61","first-page":"1665","article-title":"Multiple mechanisms of tumorigenesis in E??-myc transgenic mice","volume":"53","author":"Sidman","year":"1993","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nature13537","article-title":"Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis","volume":"511","author":"Kress","year":"2014","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17467-z","article-title":"H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients","volume":"11","author":"Schleich","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2008-10-182758","article-title":"The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy","volume":"114","author":"Ellis","year":"2009","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2015-03-632984","article-title":"Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies","volume":"126","author":"Matthews","year":"2015","journal-title":"Blood"},{"key":"ref_68","first-page":"1","article-title":"Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-14-3068","article-title":"Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma","volume":"21","author":"Amengual","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Winkler, R., M\u00e4gdefrau, A.-S., Kleemann, M., Beyer, M., Linke, K., Hansen, L., Schaffer, A.-M., Hoffmann, M.E., Poepsel, S., and Heyd, F. (2021). Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. BioRxiv.","DOI":"10.1101\/2021.06.01.445760"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bobrowska, A., Paganetti, P., Matthias, P., and Bates, G.P. (2011). Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020696"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-46555-4","article-title":"HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge","volume":"9","author":"Rosenjack","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Imai, Y., Hirano, M., Kobayashi, M., Futami, M., and Tojo, A. (2019). HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers, 11.","DOI":"10.3390\/cancers11040475"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","author":"Doose","year":"2021","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2016-08-736066","article-title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies","volume":"130","author":"Bobrowicz","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_80","first-page":"1","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade-resistant b-cell lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2013-02-485441","article-title":"Sirtuin and pan-class I\/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma","volume":"122","author":"Amengual","year":"2013","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature22353","article-title":"The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3\u00df inhibition","volume":"546","author":"Varano","year":"2017","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/PAS.0b013e31816b6478","article-title":"SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma","volume":"32","author":"Jang","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/path.4905","article-title":"SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells","volume":"242","author":"He","year":"2017","journal-title":"J. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1074\/jbc.M115.702076","article-title":"Loss of SIRT3 provides growth advantage for B cell malignancies","volume":"291","author":"Yu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ccell.2019.05.002","article-title":"Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1158\/0008-5472.CAN-16-2393","article-title":"SIRT3-mediated dimerization of IDH2 directs cancer cell metabolism and tumor growth","volume":"77","author":"Zou","year":"2017","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01623-w","article-title":"Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K\/Akt signaling","volume":"39","author":"Yang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Chowdhury, S., Sripathy, S., Webster, A., Park, A., Lao, U., Hsu, J.H., Loe, T., Bedalov, A., and Simon, J.A. (2020). Discovery of selective SIRT2 inhibitors as therapeutic agents in B-cell lymphoma and other malignancies. Molecules, 25.","DOI":"10.3390\/molecules25030455"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"112861","DOI":"10.1016\/j.ejmech.2020.112861","article-title":"Current development of CBP\/p300 inhibitors in the last decade","volume":"209","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","article-title":"Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression","volume":"6","author":"Ogiwara","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2014-08-594655","article-title":"MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development","volume":"125","author":"Sheikh","year":"2015","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","article-title":"Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth","volume":"560","author":"Baell","year":"2018","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/0008-5472.CAN-20-2379","article-title":"Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis","volume":"80","author":"Farria","year":"2020","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.18632\/oncotarget.27226","article-title":"GCN5 HAT inhibition reduces human Burkitt lymphoma cell survival through reduction of MYC target gene expression and impeding BCR signaling pathways","volume":"10","author":"Farria","year":"2019","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nature06055","article-title":"Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response","volume":"448","author":"Gorrini","year":"2007","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejmech.2011.11.001","article-title":"6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site","volume":"47","author":"Ghizzoni","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41589-019-0264-z","article-title":"Bromodomain inhibition of the coactivators CBP\/EP300 facilitate cellular reprogramming","volume":"15","author":"Ebrahimi","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrm3953","article-title":"Getting up to speed with transcription elongation by RNA polymerase II","volume":"16","author":"Jonkers","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Hoke","year":"2013","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.21253","article-title":"Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"6","author":"Aird","year":"2017","journal-title":"Elife"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","article-title":"BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression","volume":"4","author":"Cummin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.180505","article-title":"Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma","volume":"104","author":"Petazzi","year":"2019","journal-title":"Haematologica"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for Leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res."},{"key":"ref_122","first-page":"CD-20-0751","article-title":"Targeting p300\/CBP axis in lethal prostate cancer","volume":"44","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-20-2946","article-title":"SMARCA2 is a novel interactor of NSD2 and regulates pro-metastatic PTP4A3 through chromatin remodeling in t(4;14) multiple myeloma","volume":"81","author":"Chong","year":"2021","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/acs.jmedchem.5b00256","article-title":"Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition","volume":"59","author":"Theodoulou","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ymeth.2019.11.003","article-title":"Emerging tools to investigate bromodomain functions","volume":"184","author":"Filippakopoulos","year":"2020","journal-title":"Methods"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13525","article-title":"Targeting both BET and CBP\/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma","volume":"106","author":"Ryan","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1021\/acs.jmedchem.0c00478","article-title":"4-Acyl Pyrroles as Dual BET-BRD7\/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines","volume":"63","author":"Regenass","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"127671","DOI":"10.1016\/j.bmcl.2020.127671","article-title":"Current status in the discovery of dual BET\/HDAC inhibitors","volume":"31","author":"Ren","year":"2021","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin\u2019s Lymphoma and Mantle Cell Lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bjh.16008","article-title":"Phase 1\u20132 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma","volume":"186","author":"Spurgeon","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2019.1672052","article-title":"Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies","volume":"61","author":"Siddiqi","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study","volume":"134","author":"Falchi","year":"2019","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/bloodadvances.2018019240","article-title":"Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)","volume":"2","author":"Drott","year":"2018","journal-title":"Blood Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: Results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.exphem.2015.06.004","article-title":"BET bromodomain inhibitors in leukemia","volume":"43","author":"Basheer","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/leu.2016.182","article-title":"Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors","volume":"31","author":"Donato","year":"2017","journal-title":"Leukemia"},{"key":"ref_148","unstructured":"(2021, November 16). ClinicalTrials.gov Database, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000479230","article-title":"A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma","volume":"93","author":"Puvvada","year":"2017","journal-title":"Oncology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048","article-title":"41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","volume":"29","author":"Blum","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2019-124741","article-title":"The BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/S2152-2650(20)30900-9","article-title":"A Phase 1b\/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed\/Refractory Follicular Lymphoma","volume":"20","author":"Leonard","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048.001","article-title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","volume":"29","author":"Harb","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/acs.biochem.5b01073","article-title":"Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins","volume":"55","author":"Milosevich","year":"2016","journal-title":"Biochemistry"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., and Wang, J. (2015). Integrative analysis of 111 reference human epigenomes. Nature, 518, 317\u2013329.","DOI":"10.1038\/nature14248"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response","volume":"37","author":"Teater","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41375-019-0392-1","article-title":"EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation","volume":"33","author":"Herviou","year":"2019","journal-title":"Leukemia"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-Targeted Therapies in Cancer: Hype or a Reality","volume":"80","author":"Eich","year":"2020","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bcj.2015.37","article-title":"The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells","volume":"5","author":"Lai","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/s41375-020-0908-8","article-title":"CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP\/EP300-mutated lymphomas","volume":"34","author":"Veazey","year":"2020","journal-title":"Leukemia"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/MCB.00923-08","article-title":"Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells","volume":"28","author":"Wang","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"Koh","year":"2015","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Kuplast","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2018-02-831438","article-title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","volume":"132","author":"Lu","year":"2018","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41590-018-0273-1","article-title":"Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis","volume":"20","author":"Hatzi","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3324\/haematol.2016.144964","article-title":"Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs","volume":"102","author":"Mathur","year":"2017","journal-title":"Haematologica"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gene.2012.01.003","article-title":"Structural biology of the chromodomain: Form and function","volume":"496","author":"Eissenberg","year":"2012","journal-title":"Gene"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1873-3468.13021","article-title":"Structural and histone binding studies of the chromo barrel domain of TIP60","volume":"592","author":"Zhang","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1126\/science.1125162","article-title":"Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A","volume":"312","author":"Huang","year":"2006","journal-title":"Science"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature04835","article-title":"ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression","volume":"442","author":"Shi","year":"2006","journal-title":"Nature"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.1074\/jbc.M113.525279","article-title":"Methyllysine reader plant homeodomain (PHD) finger protein 20-like 1 (PHF20L1) antagonizes DNA (cytosine-5) methyltransferase 1 (DNMT1) proteasomal degradation","volume":"289","author":"Terragni","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1073\/pnas.0608721104","article-title":"Role of the chromobox protein CBX7 in lymphomagenesis","volume":"104","author":"Scott","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/MCB.26.7.2560-2569.2006","article-title":"Mouse Polycomb Proteins Bind Differentially to Methylated Histone H3 and RNA and Are Enriched in Facultative Heterochromatin","volume":"26","author":"Bernstein","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/gad.415507","article-title":"The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells","volume":"21","author":"Bracken","year":"2007","journal-title":"Genes Dev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/acsomega.6b00120","article-title":"Structure-Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins","volume":"1","author":"Simhadri","year":"2016","journal-title":"ACS Omega"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_186","unstructured":"(2021, April 29). FDA Approves Tazemetostat for Relapsed\/Refractory Follicular Lymphoma. Available online: https:\/\/www.targetedonc.com\/view\/fda-approves-tazemetostat-for-relapsed-refractory-follicular-lymphoma."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","article-title":"EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","article-title":"EPZ011989, A potent, orally-available EZH2 inhibitor with robust in vivo activity","volume":"6","author":"Campbell","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.bmcl.2015.06.056","article-title":"Discovery, design, and synthesis of indole-based EZH2 inhibitors","volume":"25","author":"Gehling","year":"2015","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Chamorro-Jorganes, A., Ribeiro, M.L., Profitos-Peleja, N., Reyes-Garau, D., Recasens-Zorzo, C., Valero, J.G., Armengol, M., Perez-Galan, P., Butler, R., and Postigo, A. (2020, January 22\u201324). Abstract 2925: Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2 Y641mut germinal centre-derived lymphoma. Proceedings of the Cancer Research, Philadelphia, PA, USA. American Association for Cancer Research (AACR).","DOI":"10.1158\/1538-7445.AM2020-2925"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","article-title":"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase i Clinical Trials for B-Cell Lymphomas","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2021.39.15_suppl.3104","article-title":"Phase 1\/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors","volume":"39","author":"Lakhani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to ezh2 inhibitors in diffuse large b-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_199","first-page":"4070","article-title":"First-in-Human Study of the EZH1\/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas\u2014Preliminary Results","volume":"130","author":"Maruyama","year":"2017","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","article-title":"Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0959-437X(98)80134-2","article-title":"The histone tails of the nucleosome","volume":"8","author":"Luger","year":"1998","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2008.02.014","article-title":"Histone Ubiquitination: Triggering Gene Activity","volume":"29","author":"Weake","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1073\/pnas.1735528100","article-title":"Histone sumoylation is associated with transcriptional repression","volume":"100","author":"Shiio","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1139\/O09-053","article-title":"H3 phosphorylation: Dual role in mitosis and interphaseThis paper is one of a selection of papers published in this Special Issue entitled 30th Annual International Asilomar Chromatin and Chromosomes Conference and has undergone the Journal\u2019s usual peer r","volume":"87","author":"Drobic","year":"2009","journal-title":"Biochem. Cell Biol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12253-012-9534-8","article-title":"Mitotic Failures in Cancer: Aurora B Kinase and its Potential Role in the Development of Aneuploidy","volume":"18","author":"Hegyi","year":"2012","journal-title":"Pathol. Oncol. Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1369\/0022155415576966","article-title":"High Phosphohistone H3 Expression Correlates with Adverse Clinical, Biological, and Pathological Factors in Neuroblastomas","volume":"63","author":"Ramani","year":"2015","journal-title":"J. Histochem. Cytochem."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/PAS.0b013e31827e50fa","article-title":"Mitotic Rate in Melanoma","volume":"37","author":"Hale","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.humpath.2015.10.012","article-title":"Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of \u201chot spots\u201d in fibroepithelial tumors of the breast","volume":"49","author":"Ginter","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ajcp\/aqz003","article-title":"The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study with Ki-67 and H&E Mitotic Count","volume":"151","author":"Khieu","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000477737","article-title":"Distinct Dynamics of Mitotic Transition in B-Cell Lymphoma and Reactive B-Cell Lymphoproliferations Determined by H3S10 Phosphohistone Immunolabeling","volume":"84","author":"Hegyi","year":"2017","journal-title":"Pathobiology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","article-title":"Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases","volume":"22","author":"Crosio","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/labinvest.2009.106","article-title":"Analysis of Aurora B kinase in non-Hodgkin lymphoma","volume":"89","author":"Ikezoe","year":"2009","journal-title":"Lab. Investig."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-18-0577","article-title":"Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma","volume":"18","author":"Ashton","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab\/Vincristine in Relapsed\/Refractory Aggressive B-cell Lymphoma","volume":"24","author":"Kelly","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/onc.2011.335","article-title":"Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin","volume":"31","author":"Huertas","year":"2012","journal-title":"Oncogene"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1538-7445.AM2012-3845","article-title":"Abstract 3845: Antitumor activity of SEL120: An orally available dual inhibitors of Haspin\/CDK9, for standalone and combination therapy with AuroraB inhibitors in solid tumors and hematopoietic malignancies. In Proceedings of the Experimental and Molecular Therapeutics","volume":"72","author":"Rzymski","year":"2012","journal-title":"Am. Assoc. Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2012.03.017","article-title":"Janus Kinase Deregulation in Leukemia and Lymphoma","volume":"36","author":"Chen","year":"2012","journal-title":"Immunity"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"E7260","DOI":"10.1073\/pnas.1610970113","article-title":"Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma","volume":"113","author":"Rui","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2019-03-900951","article-title":"JAK inhibitors and risk of B-cell lymphomas","volume":"133","author":"Rumi","year":"2019","journal-title":"Blood"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41423-019-0320-3","article-title":"JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis","volume":"17","author":"Nocturne","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/nar\/gkab032","article-title":"SUMOylation regulates the protein network and chromatin accessibility at glucocorticoid receptor-binding sites","volume":"49","author":"Paakinaho","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2018.08.020","article-title":"Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology","volume":"436","author":"Qu","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1074\/jbc.M706307200","article-title":"Nuclear Tumor Necrosis Factor Receptor-associated Factor 6 in Lymphoid Cells Negatively Regulates c-Myb-mediated Transactivation through Small Ubiquitin-related Modifier-1 Modification","volume":"283","author":"Pham","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10555-013-9434-8","article-title":"Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis","volume":"32","author":"Thompson","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1038\/bcj.2017.8","article-title":"The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells","volume":"7","author":"Nishida","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Nagel, S., Ehrentraut, S., Tomasch, J., Quentmeier, H., Meyer, C., Kaufmann, M., Drexler, H.G., and MacLeod, R.A.F. (2013). Ectopic Expression of Homeobox Gene NKX2-1 in Diffuse Large B-Cell Lymphoma Is Mediated by Aberrant Chromatin Modifications. PLoS ONE, 8.","DOI":"10.1371\/annotation\/3989404d-132f-4f07-a39e-c060d9094611"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/253\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:54:19Z","timestamp":1760169259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":228,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010253"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010253","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202111.0317.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,27]]}}}